Archives of physical medicine and rehabilitation · 2012
Is spastic muscle echo intensity related to the response to botulinum toxin type A in patients with stroke? A cohort study.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Picelli Alessandro, Bonetti Paola, Fontana Carla, Barausse Martina, Dambruoso Francesca, Gajofatto Francesca, Girardi Paolo, Manca Mario, Gimigliano Raffaele, Smania Nicola
Аннотация
OBJECTIVE: To investigate the relationship between gastrocnemius muscle echo intensity and response to botulinum toxin type A (BoNT-A) in patients with spastic equinus foot resulting from stroke.
DESIGN: Cohort study.
SETTING: University hospital.
PARTICIPANTS: Adult patients (N=56) with spastic equinus foot resulting from stroke scheduled to receive BoNT-A injection into the gastrocnemius muscle.
INTERVENTIONS: All patients were injected with BoNT-A (abobotulinumtoxinA) into the gastrocnemius muscle with an ultrasonography-guided, multisite injection technique. The toxin dose was 250U for the gastrocnemius medialis and 250U for the gastrocnemius lateralis (dilution 500U/2mL) in each patient. All patients were evaluated before and 4 weeks after BoNT-A injection.
MAIN OUTCOME MEASURES: Spastic gastrocnemius muscle echo intensity visually graded with the Heckmatt scale. Clinical assessment of the spastic gastrocnemius with the Modified Ashworth Scale, Tardieu Scale, and ankle passive range of motion.
RESULTS: Postintervention testing at 4 weeks showed overall significant improvements in the clinical assessment of the spastic gastrocnemius muscle. No significant change was observed in the echo muscle intensity of the spastic gastrocnemius after BoNT-A injection. Post hoc comparisons showed that all clinical outcomes were significantly better in those patients with echo muscle intensity of the spastic gastrocnemius graded II on the Heckmatt scale than those with grades III (P<.001) and IV (P<.001) after botulinum toxin injection.
CONCLUSIONS: These findings support the hypothesis that patients with higher spastic muscle echo intensity have a reduced response to BoNT-A.
DESIGN: Cohort study.
SETTING: University hospital.
PARTICIPANTS: Adult patients (N=56) with spastic equinus foot resulting from stroke scheduled to receive BoNT-A injection into the gastrocnemius muscle.
INTERVENTIONS: All patients were injected with BoNT-A (abobotulinumtoxinA) into the gastrocnemius muscle with an ultrasonography-guided, multisite injection technique. The toxin dose was 250U for the gastrocnemius medialis and 250U for the gastrocnemius lateralis (dilution 500U/2mL) in each patient. All patients were evaluated before and 4 weeks after BoNT-A injection.
MAIN OUTCOME MEASURES: Spastic gastrocnemius muscle echo intensity visually graded with the Heckmatt scale. Clinical assessment of the spastic gastrocnemius with the Modified Ashworth Scale, Tardieu Scale, and ankle passive range of motion.
RESULTS: Postintervention testing at 4 weeks showed overall significant improvements in the clinical assessment of the spastic gastrocnemius muscle. No significant change was observed in the echo muscle intensity of the spastic gastrocnemius after BoNT-A injection. Post hoc comparisons showed that all clinical outcomes were significantly better in those patients with echo muscle intensity of the spastic gastrocnemius graded II on the Heckmatt scale than those with grades III (P<.001) and IV (P<.001) after botulinum toxin injection.
CONCLUSIONS: These findings support the hypothesis that patients with higher spastic muscle echo intensity have a reduced response to BoNT-A.
Предметные рубрики MeSH
AdultAgedBotulinum Toxins, Type ACohort StudiesConfidence IntervalsEquinus DeformityFemaleFollow-Up StudiesHospitals, UniversityHumansInjections, IntramuscularMaleMiddle AgedMuscle SpasticityMuscle, SkeletalRisk AssessmentSensitivity and SpecificitySeverity of Illness IndexStrokeStroke RehabilitationTreatment OutcomeUltrasonography, Doppler